GLP-1 medications reduce appetite, and when total intake falls fast, muscle can fall with the fat. A 2026 systematic review and meta-analysis pooled seven randomized controlled trials. It covered 821 patients on obesity-dose GLP-1 receptor agonists. The mean change in lean mass was −1.74 kg. That is the number to plan around. The plan is protein, resistance training, and tracking what you can do. Start all three with the medication, not after weakness shows up.
Key takeaways
- In July 2026, Gallup reported that 11% of U.S. adults now take a GLP-1 medication for weight loss, up from prior years.
- In a 2026 meta-analysis of 821 patients on obesity-dose GLP-1 receptor agonists, lean mass fell by a mean of 1.74 kg. Lean mass as a share of total body weight rose by 1.81%.
- Those two findings do not conflict. Your body makeup can improve on a percentage basis while you still lose real muscle.
- Protein and structured resistance exercise have the strongest support. They work together, not as either-or choices.
- Watch function, not only the scale: how you handle stairs, how fast you recover, and whether you can rise from a chair.
- Joint pain that blocks training is a muscle problem as much as a joint problem. That is where a conservative-first orthopedic plan matters.
Why do GLP-1 medications cause muscle loss?
Intake drops faster than habits adapt
GLP-1 medications work mostly by cutting hunger and slowing how fast the stomach empties, so total intake can drop sharply within weeks. When intake falls that fast, protein often falls with it. The body then has less raw material to keep muscle.
What does muscle loss from a GLP-1 feel like?
Scale weight can drop while muscle drops right alongside it. You do not feel muscle loss in the first month. So the useful signals are strength, stamina, and what you can physically do, not the number on the scale.
This is not unique to GLP-1 medications
Muscle loss is a known part of weight loss in general, even dieting without a drug. What is different with GLP-1 therapy is the pace. Fast weight loss shrinks the window for nutrition and training to catch up.
How much muscle do you lose on a GLP-1?
The meta-analysis figures, in context
The 2026 review in the International Journal of Obesity pooled seven randomized controlled trials. They covered 821 patients on obesity-dose GLP-1 receptor agonists. Lean mass as a share of total body weight rose by 1.81%. At the same time, absolute lean mass fell by 1.74 kg, and lean mass percentage fell by 3.06%.
Read together, those results say one thing. The mix of what is left can get better while the real amount of muscle still falls. Neither figure makes GLP-1 therapy a bad choice. Both make the case for planning around it.
What is being studied next
Research is now testing whether the loss can be blunted directly. In 2026, Nature Medicine published a phase 2 trial of apitegromab. It was randomized, double-blind, and placebo-controlled. This drug targets myostatin signaling. Myostatin is a brake on muscle growth. The trial looked at preserving lean mass while adults lost weight on tirzepatide. Separately, the LEAN-PREP trial is registered on ClinicalTrials.gov. It tests whether added protein and resistance exercise preserve lean mass in adults with obesity. The adults take semaglutide or tirzepatide. Neither is a treatment you can act on today. Neither changes the basics.
How do I stop losing muscle on a GLP-1?
Protein, distributed across the day
Four groups wrote a joint advisory. They are the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. It treats protein as a core priority during GLP-1 therapy for obesity. Hitting a target once a day is not the same as spreading it out. Nausea or early fullness can make either one harder. The practical work is making protein easier to eat without cutting its quality.
Resistance training as the loading signal
Protein without loading the muscle is only half the input. Structured resistance exercise tells the body the tissue is still needed. That is why the advisory pairs the two instead of ranking them. Cleveland Clinic teaches patients how to exercise on GLP-1 medications. It suggests starting with 10 to 15 minutes a day of light activity. Walking or a stationary bike works if you are not already training. Then build as the dose goes up.
What are the signs that I’m losing muscle?
We track what you can do: how you handle stairs, recovery time between sessions, and rising from a chair without using your arms. Those measures catch a problem while it can still be reversed. Week to week, they tell you more than body weight. Reviews on keeping lean mass during GLP-1 treatment consistently put tracking next to food and exercise, not after them.
When joint pain is the thing blocking your training
The loop that forms
A painful knee or hip can make resistance training spotty. Then muscle loss speeds up, and weaker muscle loads the joint worse. That loop is common in people who start GLP-1 drugs, because the same group often carries degenerative joint disease (wear-and-tear arthritis).
Where orthobiologics honestly fit
The job of an orthobiologic here is to clear a barrier to training, not to replace it. In advanced knee osteoarthritis, trial authors frame platelet-rich plasma as a safe bridge therapy prior to joint replacement. No orthobiologic has been shown to regrow or regenerate cartilage, and we do not describe any of them that way. What each option involves is set out in our approach to conservative-first care.
Conservative measures first
We work through conservative care before anything else. Surgery is considered only after conservative measures have been exhausted. Our office is at 4477 Woodson Rd, Suite 103, St. Louis, MO 63134, next to St. Louis Lambert International Airport. Details are on our St. Louis location page.
Peptide and longevity medicine in this conversation
Discussed, not sold
Patients often ask whether a peptide could help with appetite, body makeup, or recovery while on a GLP-1. At Regen.MD, we talk about peptides as topics for care and teaching. We do not sell them. We do not present them as a shortcut around protein and training.
Where the metabolic picture matters
Three things shape how well you hold muscle during fast weight loss. They are inflammation, how well you recover, and how much muscle you start with. Those are worth checking. They belong next to the medication decision, not in place of it.
For more information, get our free guide to knee pain and treatment options.
Build the muscle-preservation plan before you need it
Regen.MD begins with a physician-led Clinical Evaluation — a review of your history, imaging, and metabolic data, and a written terrain roadmap. Evaluation is contingent upon review of your data.
Questions? Call or text us.
Frequently asked questions
How do GLP-1 medications and muscle loss end up connected?
Lower appetite cuts total intake. If protein and resistance training do not keep pace, you lose muscle with the fat. The speed of GLP-1 weight loss raises the stakes, because the nutrition and training plan has to be in place from the start, not added later. Our peptide and metabolic medicine education covers the wider physiology.
Will more protein alone protect my muscle?
Probably not on its own. Look at the joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. It pairs protein with structured resistance exercise, because loading is the signal that tells the body to keep the tissue. We work through both in the context of the conditions we evaluate.
What should I watch for if I feel weaker after starting a GLP-1?
Stairs feel harder. Recovery after activity is slower. Rising from a chair is harder. Or you stall at a weight you used to handle. Treat those as information, not normal adjustment. Take them back to your prescribing clinician before changing anything. If joint pain is part of what limits you, see our orthobiologics service page.
Can an injection fix the problem if joint pain is stopping me from training?
It can sometimes remove a barrier, but it does not replace the nutrition and strength plan. In advanced knee osteoarthritis, trial authors frame platelet-rich plasma as a safe bridge therapy prior to joint replacement. No orthobiologic has been shown to regrow cartilage. Our patient education library sets out how we frame those limits.
Who reviews my regimen?
A physician leads the Clinical Evaluation. It looks at your GLP-1 plan next to your daily function, not just your weight trend. You can read the background of Dr. Gurpreet Singh Padda, MD, MBA, MHP before requesting one.
How can I gain muscle while on a GLP-1?
Pair protein with structured resistance training, and start both when you start the medication. Protein works best spread across the day, not packed into one meal. Training is the signal that tells your body the muscle is still needed. If you are not training yet, Cleveland Clinic suggests starting with 10 to 15 minutes a day of light activity, such as walking or a stationary bike. Then build as your dose goes up.
Can you regain muscle lost on a GLP-1?
Loss caught early is the kind you can still reverse. That is why we track function, not only the scale. We watch stairs, recovery time between sessions, and rising from a chair without using your arms. When those slip, the answer is the same two levers. Spread protein across the day, and do structured resistance training. If a painful knee or hip is blocking the training, that barrier gets treated too.
Does muscle loss only happen on GLP-1 medications?
No. Losing muscle is part of weight loss in general, even dieting without a drug. What is different on a GLP-1 is the speed. Appetite and intake can drop sharply within weeks, and protein often drops with it. That short window is why the food and training plan must start on day one. Do not wait for weakness to show up.
Sources
- Gallup. In U.S., GLP-1 Usage Reaches New High. July 7, 2026. https://news.gallup.com/poll/712157/glp-usage-reaches-new-high.aspx — referenced for the finding that 11% of U.S. adults currently take GLP-1 medications for weight loss purposes.
- Effect of GLP-1 receptor agonists at doses for obesity management on muscle health: systematic review and meta-analysis of randomized controlled trials (RCTs). International Journal of Obesity, 2026. https://www.nature.com/articles/s41366-026-02118-y — referenced for the seven included studies and 821 patients, the 1.81% increase in lean mass as a proportion of total weight, the 1.74 kg decrease in absolute lean mass, and the 3.06% decrease in lean mass percentage.
- Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. American Journal of Lifestyle Medicine, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12125019/ — referenced for the emphasis on protein intake and structured resistance exercise during GLP-1-mediated weight loss.
- Lean Mass and Musculoskeletal Preservation in GLP-1-Based Obesity Treatment: Nutrition, Exercise, Supplementation, and Monitoring Strategies. Metabolites, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC13303403/ — referenced for the placement of monitoring alongside nutrition and exercise in lean mass preservation strategies.
- Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity. Obesity Reviews, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11611443/ — referenced for skeletal muscle loss as a recognized feature of weight loss generally, including caloric restriction without medication.
- Cleveland Clinic. Taking GLP-1s? Make Sure You Exercise. Patient education article, May 5, 2026. https://health.clevelandclinic.org/exercise-for-glp-1-use — referenced for the suggestion to start with 10 to 15 minutes a day of light activity such as walking or stationary cycling.
- ClinicalTrials.gov. LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide and Tirzepatide Therapy (LEAN-PREP Study). NCT06885736, Dasman Diabetes Institute, recruiting. https://clinicaltrials.gov/study/NCT06885736 — referenced for the trial testing protein plus resistance exercise for lean mass preservation in adults with obesity.
- Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial. Nature Medicine, July 2026. https://pubmed.ncbi.nlm.nih.gov/42260100/ — referenced for the phase 2 investigation of myostatin-pathway inhibition during tirzepatide-induced weight loss.